Abstract:Control of xenograft rejection in experimental models has been a challenge. The direct targeting of T cells enabled allotransplantation, but this approach has been less effective in xenotransplantation. Various genetic modifications like α-1,3 galactosyltransferase gene-knockout, transgenic expression of human complement regulatory proteins (CD46), and coagulation-regulatory protein thrombomodulin have been the key to avoiding early cardiac xenograft rejection. The potential of the CRISPR technique 1 , 2 in addition to an improved immunosuppression regimen including costimulation blockade, for example, anti-CD154mAb and anti-CD40mAb, plus elimination of the B-cell response have advanced the field. 3 , 4 With these manipulations, nonlife supporting, heterotopic cardiac xenograft survival has been extended to 945 days. 5 , 6 In their recent letter to Nature, Längin et al 7 report early, consistent survival in an experimental orthotopic cardiac xenotransplantation model. Those results demonstrate yet another milestone in moving the xenotransplant closer to a clinical application. The data by the Munich group can be considered a game changer as the authors have successfully translated the recently reported significant cardiac xenograft survival in a heterotopic position 5 to an orthotopic transplant model and have demonstrated the required life-sustaining capability of a genetically engineered pig hearts transplanted into baboon. It is not clear what regulatory agencies will consider sufficient to move forward with clinical xenotransplantation. The International Society for Heart and Lung Transplantation suggests that success in a large animal model will include 60% graft survival for a follow-up of 3 months and 50% survival in a 6 months' observation. 8 The study by Längin et al 7 included 12 transplants, with 2 baboons surviving 90 days and 2 animals surviving beyond 6 months. The first 2 transplants were electively terminated due to restriction of only 90-day survival by their study protocol. The authors then received permission to extend the survival for 6 months, and the latter 2 transplants were therefore electively terminated after crossing 6-month survival (182 and 195 days, respectively). 7 A few key findings of this study should be emphasized. According to the authors, the use of cold (−8°C) nonischemic continuous perfusion of the donor's heart in a special chamber with Steen solution 9 containing red blood cells (15% hematocrit) for 3 hours before implant appeared beneficial. Maintenance immunosuppression included anti-inflammatory drugs targeting interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF)-α. Treatment also included temsirolimus, a prodrug of rapamycin and a specific inhibitor of the phosphatidylinositol 3-protein kinase (mTOR) family that inhibits cell cycle progression. The authors demonstrated in the 2 longest-term survivors that the withdrawal of temsirolimus led to hypertrophy and physiological overgrowth of the naturally aging porcine heart in the baboon. It is unclear if temsirolimus application had been essential as directly inhibiting xenograft hypertrophy or as an immunosuppressant. Potential side effects of extended use of temsirolimus are not discussed, and it is not known whether the withdrawal of this drug was elective or due to complications. A continuous intravenous infusion of antihypertensive drugs, enalapril and metoprolol, was implemented to achieve "porcine-like" hemodynamics, with a target systolic pressure of 80 mm Hg and heart rate of 100, in an effort to further mitigate xenograft overgrowth. Controlling hemodynamic changes alone appeared insufficient to prevent xenograft overgrowth, as the addition of temsirolimus seemed necessary, suggesting that intrinsic factors beyond hemodynamic control contribute to the porcine heart. While the overall clinical success is significant, it remains difficult to tease out which of the individual therapeutics have been necessary. The mechanism by which nonischemic continuous organ perfusion is superior compared to conventional cold preservation techniques for myocardial preservation is unclear. The authors used the Steen solution 9 that has traditionally been used for lung preservation with a composition that differs from conventional crystalloid cardioplegia. Moreover, detailed mechanisms on how appropriate xenograft size is maintained remain unclear. If growth restriction is necessary, use of minipigs or growth hormone receptor-deficient pigs could hel -Abstract Truncated-

Recent progress and remaining hurdles toward clinical xenotransplantation

Xenotransplantation: Current Status in Preclinical Research

Xenotransplantation: A New Era

Current challenges in xenotransplantation

Progress in Xenotransplantation: Immunologic Barriers, Advances in Gene Editing, and Successful Tolerance Induction Strategies in Pig-To-Primate Transplantation

Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials

Progress in xenotransplantation: overcoming immune barriers

Kidney xenotransplantation: Recent progress in preclinical research

Opinions on the Future of Clinical Pig Kidney Xenotransplantation

Renal xenotransplantation: experimental progress and clinical prospects

Progress in Orthotopic Pig Heart Transplantation in Nonhuman Primates

Does Xenotransplantation Offer a Large Benefit for Human Patients?—A Reply

Clinical xenotransplantation of solid organs

Xenotransplantation: Where are we in 2008?

Current status of xenotransplantation and prospects for clinical application

Xenotransplantation: A Step Closer to Clinical Reality?

Clinical xenotransplantation: the next medical revolution?

Xenotransplantation: current status and a perspective on the future

Xenotransplantation—the current status and prospects

Introduction: The Present Status of Xenotransplantation Research

An update on xenotransplantation